TFFP (TFF Pharmaceuticals Inc.) Net Profit

Corporate emblem and logo of tffpharma.com (TFFP)

Patents for the thin-film freezing method create a powerful defensive barrier, and the aggregate net income of TFF Pharmaceuticals (TFFP) on GURU.Markets reflects current dynamics, where the value -0.02 captures this metric. The business scales through licensing technologies to pharma behemoths without incurring plant costs. Currently, management is transparently liquidating assets and selling intellectual property due to a capital deficit, while adhering to SEC regulations.

TFFP (TFF Pharmaceuticals, Inc.) Company Net Income history from 07/04/2022 to 12/21/2024

Financial and market metric breakdowns for TFF Pharmaceuticals, Inc. (TFFP)

- price and consensus price forecast:
Stock Quotes TFF Pharmaceuticals, Inc|TFFP - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization TFF Pharmaceuticals, Inc|TFFP - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share TFF Pharmaceuticals|TFFP - Company Book Value|Market-to-Book Ratio tffpharma.com|TFFP - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital TFF Pharmaceuticals|TFFP - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital TFF Pharmaceuticals Inc.|TFFP - Company Aggregate Debts|Debts to Book Value TFF Pharmaceuticals, Inc|TFFP - Company Long-Term Debt|Company Short-Term Loans and Borrowings TFF Pharmaceuticals|Intermediate Liquidity Ratio tffpharma.com
- net income and valuation multiples indicators:
TFFP - Net Profit
Fundamental valuation:TFFP TFF Pharmaceuticals, Inc
Flagship merchandise of TFF Pharmaceuticals Inc.

TFF Pharmaceuticals leverages unique patents for powder drug formulations to dictate licensing terms, which directly impacts net income dynamics. An analysis of TFF Pharmaceuticals' operating results allows for an assessment of the Fed's policy influence on margins and identifies capital overheating risks through daily profit taking, helping investors determine the safety margin of investments and the probability of a near-term asset price correction.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Theravance Biopharma, Inc. - Net Income|Profit After Payment of Taxes AQST (Aquestive Therapeutics Inc)|scPharma - Net Profit|Profit After Tax TECX|TNXP: Net Profit|Profit After Tax SXTC (China SXT Pharmaceuticals, Inc.)|Net Income EPRX|BHST: Final Profit|Company Net Income Invizyne Technologies, Inc. (EXOZ)|ORMP: Profit After Tax|Net Profit ENTX (Entera Bio)|Final Profit HYFT|ABVC BioPharma, Inc. - Net Profit|CPIX - Net Profit|Quantum BioPharma Limited (QNTM) - Company Net Income|FibroGen Corporation - Final Profit|Company Net Income Telomir Pharmaceuticals|Net Income Rani Therapeutics Inc (RANI)|Net Profit SNYR|Net Profit rallybio.com (RLYB)|Net Profit LEXX (Lexaria Bioscience Corp.)|PULM - Net Income|Pheton - Net Profit|Company Net Income Aptorum Group Limited|LYRA (Lyra Therapeutics) - Net Income|impactbiomedinc.com (IBO) - Net Profit|Net Income TNFA|YCBD (cbdMD Corp) - Profit After Payment of Taxes|Net Profit PRFX|Net Financial Result altamiratherapeutics.com|Net Profit LIPO (Lipella Pharmaceuticals, Inc.)|OPTN - Net Income|Pieris - Net Profit|PROC - Net Profit|Petros Pharmaceuticals (PTPI) - Company Net Income|QLI (qlsyy.net) - Company Net Income|Company Net Income ACELYRIN